Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma.
Hyun-Young KimIn Young YooDae Jin LimHee Jin KimSun Hee KimSang Eun YoonSeok Jin KimDuck ChoKihyun KimPublished in: Annals of laboratory medicine (2022)
Clinical application of NGF-based MRD assessment can provide valuable information for predicting disease progression in patients with MM in remission, including those with high-risk cytogenetic abnormalities.